Modifying probiotic L. lactis to secrete a fusion of Fms‐like tyrosine kinase 3 ligand (Flt3L) and OX40 ligands enables local retention and sustained release of these therapeutics, leading to immune system activation and anti‐tumour immune responses (Zhu et al. 2022). Here, TNFRSF4 is linked to neoplasm.